| Not Yet Recruiting | Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients Acute Myeloid Leukemia With Gene Mutations | Phase 2 | 2026-04-01 |
| Not Yet Recruiting | Treatment for Ph-negative ALL for Adults up to 65 Years Acute Lymphoblastic Leukemia | N/A | 2026-03-06 |
| Not Yet Recruiting | Azacytidine, Venetoclax Plus Minus Quizartinib for First Line Older/Unfit AML Patients (VENP-A-QUI) Acute Myeloid Leukemia, Adult | Phase 3 | 2026-03-01 |
| Recruiting | Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-An De Novo Multiple Myeloma, Anitocabtagene Autoleucel | Phase 2 | 2025-06-30 |
| Recruiting | Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma High Risk Smoldering Multiple Myeloma | Phase 2 | 2024-09-30 |
| Recruiting | Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Ly Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 2 | 2024-09-02 |
| Not Yet Recruiting | Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL Lymphoblastic Leukemia, Philadelphia-Positive ALL, Adult ALL | — | 2023-12-25 |
| Recruiting | Study of Elranatamab for Relapsed or Refractory Myeloma in Patients Previously Exposed to Three-drug Classes Multiple Myeloma in Relapse | Phase 2 | 2023-11-23 |
| Active Not Recruiting | Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma High-Risk de Novo Multiple Myeloma | Phase 2 | 2023-09-21 |
| Not Yet Recruiting | NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide Newly Diagnosed Multiple Myeloma | Phase 3 | 2022-10-01 |
| Not Yet Recruiting | Iberdomide-dexamethasone Alone or in Combination With Standard MM Treatment Regimens in Transplant Ineligible Multiple Myeloma | Phase 2 | 2022-09-01 |
| Unknown | Retrospective Study of the Use of Belantamab Mafodotin (Blenrep®) in Patients With Relapsed and/or Refractory RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA | — | 2022-03-24 |
| Recruiting | Study of Belantamab Mafodotin in Combination With Kd for the Treatment of Relapsed Myeloma Patients, Refractor Relapsed Multiple Myeloma | Phase 1 / Phase 2 | 2021-12-20 |
| Unknown | Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT) | — | 2021-11-30 |
| Active Not Recruiting | Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Multiple Myeloma | Phase 2 | 2021-04-07 |
| Unknown | Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Leukemia, Myeloid, Acute, De Novo, Age More 60yr | Phase 1 / Phase 2 | 2020-11-04 |
| Completed | Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Ag Newly Diagnosed Secondary or High Risk AML | Phase 2 | 2019-12-26 |
| Unknown | A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemothe Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2019-12-26 |
| Completed | Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia Chronic Lymphocytic Leukemia- Binet Staging System | Phase 3 | 2019-12-09 |
| Recruiting | Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults Acute Lymphoblastic Leukemia | N/A | 2019-11-25 |
| Completed | A Retrospective Epidemiologic Registry to Gain Insight Into the Characteristics and Prognosis of AML Patients Acute Myeloid Leukemia | — | 2019-11-01 |
| Unknown | Molecular Diagnostic Platform for AML Acute Myeloid Leukemia (AML) | — | 2019-10-01 |
| Active Not Recruiting | Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Leukemia, Myeloid, Acute | Phase 3 | 2019-09-24 |
| Completed | Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Ty Acute Myeloid Leukemia | Phase 2 | 2019-09-05 |
| Active Not Recruiting | Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years Newly Diagnosed Multiple Myeloma | Phase 3 | 2018-10-22 |
| Completed | Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML Acute Myeloid Leukemia | Phase 1 | 2018-07-17 |
| Active Not Recruiting | SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma Refractory Multiple Myeloma | Phase 2 | 2018-07-15 |
| Terminated | REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | 2018-07-01 |
| Terminated | PETHEMA-BLIN-01/PET069014 (BLIN-01) Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL | Phase 2 | 2018-06-30 |
| Unknown | Study of Prognostic Factors in Adult Lymphoblastic Lymphoma Lymphoblastic Lymphoma | — | 2018-06-15 |
| Completed | Retrospective Viability Study of the PETHEMA-POMCIDEX Clinical Practice Guidelines for the Treatment of Patien Relapsed and Refractory Multiple Myeloma | — | 2018-04-27 |
| Unknown | Carfilzomib, Cyclophosphamide, Dexamethasone in Multiple Myeloma Multiple Myeloma | Phase 2 | 2017-12-18 |
| Completed | Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Seque Acute Myeloid Leukemia | — | 2017-10-06 |
| Unknown | Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab Chronic Lymphocytic Leukemia | Phase 2 | 2017-09-07 |
| Terminated | Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple Myeloma Multiple Myeloma | Phase 1 | 2017-01-01 |
| Unknown | Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia ALL | Phase 2 | 2016-06-01 |
| Completed | Pembrolizumab (MK-3475) in MM Patients With Residual Disease Multiple Myeloma | Phase 2 | 2016-06-01 |
| Completed | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Multiple Myeloma | Phase 1 / Phase 2 | 2015-09-01 |
| Unknown | GEM-CLARIDEX: Ld vs BiRd Multiple Myeloma | Phase 3 | 2015-09-01 |
| Completed | VILMA: Therapeutic Results in Acute Mieloblastic Leukemia in Patients Older Than 60 Years AML | — | 2015-07-01 |
| Unknown | Epidemiologic Registry PETHEMA LMA 2015 AML | — | 2015-05-01 |
| Active Not Recruiting | Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma Smoldering Multiple Myeloma | Phase 2 | 2015-05-01 |
| Completed | CML Treated With Bosutinib After Relapse Chronic Myeloblastic Leukaemia | Phase 2 | 2015-05-01 |
| Completed | Trial Studying Maintenance Treatment With Lenalidomide and Dexamethasone Versus Lenalidomide, Dexamethasone an Multiple Myeloma | Phase 3 | 2014-11-01 |
| Completed | Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine (Fluga Scheme) in Elderly Patients With Newly Diagnose Acute Myeloid Leukemia | Phase 3 | 2014-10-01 |
| Unknown | Treatment of Mature B-ALL and Burkitt Lymphoma (BL) in Adult Patients. BURKIMAB-14. Mature B-Cell Leukemia Burkitt Type, Burkitt Lymphoma (BL), Unclassifiable Lymphoma Between DCBL and BL | Phase 2 | 2014-01-01 |
| Completed | Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old Multiple Myeloma | Phase 3 | 2013-09-01 |
| Unknown | Dasatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase Chronic Myeloid Leukemia | Phase 2 | 2013-03-01 |
| Completed | Treatment of Relapsed or Refractory Acute Myeloblastic Leukemia Acute Myeloblastic Leukemia | Phase 1 / Phase 2 | 2012-07-01 |
| Unknown | Clinical Guidelines for APL Treatment APL | Phase 4 | 2012-06-01 |
| Completed | Treatment of Acute Lymphoblastic Leukemia HIGH RISK BCR / ABL NEGATIVE IN ADULTS Acute Lymphoblastic Leukemia | — | 2012-02-01 |
| Completed | Epidemiologic Registry PETHEMA LMA 2013 AML | — | 2012-01-01 |
| Completed | Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma Multiple Myeloma | Phase 2 | 2011-07-01 |
| Completed | Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan Multiple Myeloma | Phase 2 | 2011-02-01 |
| Terminated | LENA-LMA-5:Lenalidomide in Acute Myeloid Leukemia (AML) AML | Phase 4 | 2011-01-01 |
| Unknown | PETHEMA-LMA10: Treatment of Acute Myeloblastic Leukemia (AML) in Patients Less Than or Equal to 65 Years Acute Myeloblastic Leukemia | N/A | 2010-12-01 |
| Completed | Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed Primary Systemic Amyloidosis | Phase 2 | 2010-10-01 |
| Terminated | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age Greater Than or Equa Acute Myelogenous Leukemia | Phase 2 | 2010-09-01 |
| Unknown | PETHEMA LAL-07FRAIL: All Treatment In Fragile Patients Ph' Negative Over 55 Years Acute Lymphoblastic Leukemia | Phase 4 | 2010-05-01 |
| Completed | Zoledronic Acid in Patients With Multiple Myeloma and Asymptomatic Biochemical Relapse Multiple Myeloma | Phase 4 | 2010-04-01 |
| Completed | Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple My Multiple Myeloma | Phase 2 | 2010-03-01 |
| Completed | Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagn Acute Myeloblastic Leukaemia | Phase 1 / Phase 2 | 2009-09-01 |
| Terminated | PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of Neuromeningeal Infiltration in Ac Acute Lymphoblastic Leukemia | Phase 3 | 2009-09-01 |
| Terminated | SIMIDIS: Azacitidine and Beta Erythropoietin Treatment in Patients With Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 2 | 2009-02-01 |
| Terminated | A Prospective, Open, Non-randomized Phase I/II Study of Therapeutic Angiogenesis in Diabetic Patients With Cri Diabetic Patients With Critic Ischemia in Lower Limbs Who Are Administered With CD133+ Cells Mobilized by G-CSF | Phase 1 / Phase 2 | 2009-01-01 |
| Completed | ZAR2007: R-CHOP in Folicular Lymphoma Patients no Treated Previously. Consolidation With 90Y Ibritumomab Tiuxe Lymphoma | Phase 2 | 2008-12-01 |
| Completed | Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2008-04-01 |
| Unknown | Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Acute Lymphoblastic Leukemia Ph Positive | Phase 4 | 2008-01-01 |
| Completed | Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Acute Lymphobkastic Leukemia | Phase 4 | 2008-01-01 |
| Completed | MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Multiple Myeloma | Phase 2 | 2007-11-01 |
| Completed | LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO Acute Myeloblastic Leukemia | Phase 4 | 2007-10-01 |
| Completed | Treatment of Relapsed Promyelocytic Leukemia With Arsenic Trioxide (ATO) Acute Promyelocytic Leukemia | Phase 4 | 2007-07-01 |
| Unknown | Protocol For the Treatment Acute Lymphoblastic Leukemia With Ph 'Negative in Elderly Patients (> 55 Years) Acute Lymphoblastic Leukemia | Phase 4 | 2007-06-30 |
| Completed | QUIREDEX: Revlimid (Lenalidomide) and Dexamethasone (ReDex) Treatment Versus Observation in Patients With Smol Multiple Myeloma | Phase 3 | 2007-05-01 |
| Unknown | Treatment of Acute Lymphoblastic Leukemia Ph '(BCR / ABL) Positive Patients Aged > 55 Years Acute Lymphoblastic Leukemia Ph Positive | N/A | 2007-01-01 |
| Completed | Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bort Multiple Myeloma | Phase 4 | 2007-01-01 |
| Completed | AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Leukemia, Lymphoma | Phase 4 | 2006-11-01 |
| Completed | LINFOTARGAM: Treatment With Chemotherapy Plus Rituximab and Highly Active Antiretroviral Therapy in Patients W HIV Infections, Diffuse Large B Cell Lymphoma | Phase 4 | 2006-10-01 |
| Completed | Antifungal Use in Oncohematological Neutropenic Patients Invader Fungal Infection | Phase 4 | 2006-08-01 |
| Completed | Rituximab Combined With Chemotherapy in Burkitt's Lymphoma Acute Lymphoblastic Leukemia, Burkitt's Lymphoma | Phase 2 | 2006-08-01 |
| Completed | Depocyte in the Treatment of CNS Relapse in Patients With Lymphoblastic Leucemia or Very Aggressive Lymphoma Lymphoblastic Leukemia, Lymphoma | Phase 2 | 2006-03-01 |
| Completed | GEM05 for Patients With Multiple Myeloma Under 65 Years Multiple Myeloma | Phase 3 | 2006-03-01 |
| Completed | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis Acute Myeloid Leukemia, Allogeneic Haematopoietic Progenitor Cell Transplant | Phase 2 | 2006-01-01 |
| Completed | TAMOVALCIR in Allogenic Hematopoietic Progenitors Transplant Cytomegalovirus Infection | Phase 2 | 2005-11-01 |
| Completed | VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma Multiple Myeloma | Phase 2 | 2005-08-01 |
| Completed | Treatment of Newly Diagnosed Patients With Acute Promyelocytic Leukemia (PETHEMA LPA 2005) Acute Promyelocytic Leukemia | Phase 4 | 2005-07-01 |
| Completed | LAL-AR-N-2005:Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 4 | 2005-06-01 |
| Completed | GEM05 for Patients With Multiple Myeloma More Than 65 Years Old Multiple Myeloma | Phase 3 | 2005-03-01 |
| Completed | Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients. Multiple Myeloma | Phase 1 / Phase 2 | 2004-04-01 |
| Completed | Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection Candidiasis, Aspergillosis | — | 2004-03-01 |
| Completed | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic Chronic Myeloid Leukaemia | Phase 4 | 2003-07-01 |
| Completed | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 4 | 2003-05-01 |
| Completed | Treatment of High Risk Adult Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 4 | 2003-01-01 |
| Completed | Meropenem Versus Meropenem Plus Glycopeptide in Patients With Febrile Neutropenia After Allogenic Blood Stem C Allogenic Blood Stem Cell Transplantation, Febrile Neutropenia | — | 2002-11-01 |
| Completed | Glivec in Ph Positive Lymphoblastic Leukemia Acute Lymphoblastic Leukemia, Cromosome Philadelphia Positive | Phase 2 | 2002-06-01 |
| Completed | Antithymocyte Globulin and Cyclosporine in Treating Low Risk Patients With Myelodysplastic Syndrome Myelodysplastic Syndrome | Phase 4 | 2002-05-01 |
| Completed | LAL-BR/2001: Study Treatment to Low Risk ALL Acute Lymphoblastic Leukemia | Phase 4 | 2001-06-01 |
| Completed | Pethema Multiple Myeloma 2000 Multiple Myeloma | Phase 3 | 2000-01-01 |
| Completed | LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 4 | 2000-01-01 |
| Completed | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) Acute Promyelocytic Leukemia | Phase 4 | 1999-03-01 |
| Completed | Treatment of Acute Myeloblastic Leukemia in Younger Patients Acute Myeloblastic Leukemia | — | 1999-01-01 |
| Completed | Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years Acute Myeloblastic Leukaemia | Phase 4 | 1998-10-01 |
| Completed | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Mye Myelodysplastic Syndrome, Acute Myeloblastic Leukemia | Phase 4 | 1998-07-01 |
| Completed | PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Acute Lymphoblastic Leukemia | Phase 4 | 1996-06-01 |